03/10
Headlines

NYSEMKT:SYN

Biotech New Highs: EXACT Sciences Corporation (NASDAQ:EXAS), Synthetic Biologics (NYSEMKT:SYN), Amgen (NASDAQ:AMGN), Prothena Corporation (NASDAQ:PRTA)

Kristen Barton02 mins

A colon cancer screening test under development at Madison-based Exact Sciences Corp. (NASDAQ:EXAS) can detect early-stage cancer better than other noninvasive approaches, according to a study published online Wednesday. EXACT Sciences Corporation (NASDAQ:EXAS) stock performance was 0.21% in last session and finished the day at $14.45. Traded volume was 7.74 million shares in the last…

Read More

Biotech Gainers: Inovio Pharmaceuticals Inc (NYSEMKT:INO), Galena Biopharma (NASDAQ:GALE), CEL-SCI Corporation (NYSEMKT:CVM), Synthetic Biologics (NYSEMKT:SYN)

Mark DeFrance02 mins

Inovio Pharmaceuticals Inc (NYSEMKT:INO)’s shares climbed 4.96% to $3.60. The company on Mar. 17 reported financial results for the fourth quarter and year ended Dec. 31, 2013. Total revenue was $1.7 million and $13.5 million for the quarter and year ended December 31, 2013, as compared to $1.1 million and $4.1 million for the same…

Read More

Biotech Unusual Volume: Tengion (OTCMKTS:TNGN), Alseres Pharmaceuticals (OTCMKTS:ALSE), Fate Therapeutics (NASDAQ:FATE), Synthetic Biologics (NYSEMKT:SYN)

Colin Pettis02 mins

Tengion, Inc. (OTCMKTS:TNGN) on Mar. 3 issued notices to the holders (the “2012 Investors”) of senior secured notes issued on October 2, 2012 and to the holders (the “2013 Investors” and together with the 2012 Investors, the “Investors” and each, an “Investor”) of senior secured notes issued on June 28, 2013 stating that the Company…

Read More

Biotech Stocks New Highs: Fate Therapeutics (NASDAQ:FATE), Synthetic Biologics (NYSEMKT:SYN), Celladon Corp (NASDAQ:CLDN), Kindred Biosciences (NASDAQ:KIN)

Colin Pettis02 mins

Fate Therapeutics, Inc. (NASDAQ:FATE) announced that it has enrolled the first patient in its phase II study (PUMA − P rohema in UM bilical cord blood transplant in A dults) on Prohema. Fate Therapeutics Inc. (NASDAQ:FATE) stock performance was 27.14% in last session and finished the day at $11.15. Traded volume was 295,227.00 shares in…

Read More

Biotech Top Gainer: Ariad Pharmaceuticals (NASDAQ:ARIA), CEL-SCI Corporation (NYSEMKT:CVM), Synthetic Biologics (NYSEMKT:SYN), Agenus Inc. (NASDAQ:AGEN)

Chris Lewis02 mins

Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) on Feb. 25 reported financial results for the fourth quarter and full year ended December 31, 2013 and provided an update on corporate developments. Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) stock performance was 8.79% in last session and finished the day at $8.17. Traded volume was 18.32 million shares in the last session…

Read More

Biotech Gainers: Arrowhead Research (NASDAQ:ARWR), DARA Biosciences (NASDAQ:DARA), Synthetic Biologics (NYSEMKT:SYN), Oncothyreon (NASDAQ:ONTY)

Mark DeFrance02 mins

Equities research analysts at Deutsche Bank assumed coverage on shares of Arrowhead Research Corp (NASDAQ:ARWR) in a research note issued to investors on Wednesday, TheFlyOnTheWall.com reports. The firm set a “buy” rating and a $45.00 price target on the stock. Arrowhead Research Corp (NASDAQ:ARWR) stock performance was 24.46% in last session and finished the day…

Read More